<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46945">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495077</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOT-19</org_study_id>
    <nct_id>NCT02495077</nct_id>
  </id_info>
  <brief_title>Effects of Inhibiting Early Inflammation in Kidney Transplant Patients</brief_title>
  <official_title>Randomized Controlled Trial of Infliximab (RemicadeÂ®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials in Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During transplant surgery, there is a period of time when a donated kidney is removed from a
      donor's body and stored until the time of the transplant surgery. The storage procedure
      results in buildup of various proteins within the kidney that can injure the donated kidney
      after it is transplanted. One of these proteins is tumor necrosis factor-alpha (TNF-alpha).

      The purpose of this study is to evaluate whether taking infliximab, which blocks TNF-alpha,
      just prior to transplant surgery along with usual transplant medicines will protect the
      donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy
      for a longer period of time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between the mean eGFR (modified MDRD) in the experimental vs. control groups.</measure>
    <time_frame>24-Month post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR)</measure>
    <time_frame>6 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR).</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BANFF grades of first Acute Cellular Rejections (ACR).</measure>
    <time_frame>6 month post-transplantation</time_frame>
    <description>Based on BANFF 2007 Scoring Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR) or borderline rejection.</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute cellular rejection (BPAR) or borderline rejection</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection (AMR)</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection (AMR).</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection AMR or suspicious for AMR</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with biopsy proven acute antibody mediated rejection AMR or suspicious for AMR.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BANFF grades of first AMR.</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BANFF chronicity scores &gt; or equal 2.</measure>
    <time_frame>24 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BANFF chronicity scores Change Between implantation and 24 month biopsies.</measure>
    <time_frame>24 month post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR between 3 months and 24 months</measure>
    <time_frame>24 month post-transplantation</time_frame>
    <description>As measured by both MDRD and Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR between post-transplant nadir and 24 months</measure>
    <time_frame>24 month post-transplantation</time_frame>
    <description>As measured by both MDRD and CKD-EPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR Values</measure>
    <time_frame>On days 7, 30, 90, and 180 post-transplantation</time_frame>
    <description>As measured by both MDRD and CKD-EPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with death or graft failure.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with only graft failure.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that required at least one dialysis treatment.</measure>
    <time_frame>1 week post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dialysis sessions.</measure>
    <time_frame>8 weeks post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delayed graft function (DGF) defined from transplantation to the last required dialysis treatment.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of primary non-function (PNF), defined as for dialysis-dependency for more than 3 months.</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (immediately after surgery) in serum creatinine and serum creatinine concentration.</measure>
    <time_frame>24, 48 and 72 hours post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event (ACR, AMR, or hospitalization for infection and or malignancy)</measure>
    <time_frame>2 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 5 post-transplantation</time_frame>
    <description>The proportion of patients with a serum creatinine of more than 3 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Slow Graft Function (SGF)</measure>
    <time_frame>Day 2 and 7 post-transplantation</time_frame>
    <description>Creatinine reduction ratio (CRR) defined as the first creatinine on the day divided by the first creatinine after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 5 post-transplantation</time_frame>
    <description>The proportion of patients whose day 5 serum CRR was less than 70%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function (SGF)</measure>
    <time_frame>Day 2 post-transplantation</time_frame>
    <description>The proportion of patients whose day 2 serum CRR was less than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Slow Graft Function</measure>
    <time_frame>1 week post-transplantation</time_frame>
    <description>Proportion of subjects who need dialysis after 1 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with any infection requiring hospitalization or resulting in death.</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Mycobacterial or fungal infections</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CMV viremia require a change in immunosuppression or anti-viral treatment as per standard of care at the site</measure>
    <time_frame>5 years post-transplantation</time_frame>
    <description>as per standard of care at the site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BK viremia that require a change in immunosuppression or anti-viral treatment as per standard of care at the site.</measure>
    <time_frame>5 years</time_frame>
    <description>as per standard of care at the site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with malignancy.</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with impaired wound healing manifested by wound dehiscence, wound infection, or hernia at the site of the transplant incision</measure>
    <time_frame>5 years post-transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rATG is co-administered with anti-TNFa (infliximab/Remicade) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rabbit anti-thymocyte globulin (rATG, Thymoglobulin) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>A single dose, of 3mg/kg infusion</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Administered at a target dose of 2000mg daily, as tolerated, until study closure</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>FR-900506</other_name>
    <other_name>Prograf</other_name>
    <other_name>Prograft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Anti-Thymocyte Globulin [Rabbit]</other_name>
    <other_name>Rabbit ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Tylenol, 600 to 1000mg by mouth or
Suppository form</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Infliximab</intervention_name>
    <description>A single dose is volume matched to Infliximab (250mL) infusion</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be able to understand and provide consent

          2. Recipients of deceased donor kidney transplants

          3. Recipients of HLA mismatched kidneys

          4. Recipients who are virtual cross match negative as determined by local HLA lab

          5. Donor kidneys from deceased donors and donors after cardiac death (DCD) with Kidney
             Donor Profile Indices (KDPI) ranging from &gt;35 to &lt;95

          6. Female participants of childbearing potential must have a negative pregnancy test
             upon study entry

        Exclusion Criteria:

          1. Inability or unwillingness of a participant to give written informed consent or
             comply with study protocol

          2. Recipients of living donor transplants

          3. Presence of other transplanted organ or co-transplanted organ

          4. Recipients of kidneys with zero HLA mismatches

          5. HIV+ recipients

          6. EBV negative recipients

          7. Hepatitis B surface antigen positive kidney transplant recipients

          8. Hepatitis B core antibody positive kidney transplant recipients

          9. Hepatitis B negative kidney transplant recipients that receive transplants from
             Hepatitis B core antibody positive donor

         10. Hepatitis C Virus positive (HCV+) patients who are either untreated or have failed to
             demonstrate sustained viral remission for more than 12 months after anti-viral
             treatment

         11. Recipients with a previous history of active TB

         12. Patients with a positive test for TB exposure (PPD, QuantiFERON, ELISPOT) without
             history of active infection who have NOT completed a full course of INH therapy

         13. Recipients with a positive virtual cross match as determined by the local HLA lab

         14. Any infection at the time of transplantation

         15. Severe congestive heart failure (NYHA functional class III or higher)

         16. Subjects with a known hypersensitivity to any murine/ mouse proteins.

         17. Subjects with any history of receiving any anti-TNF products

         18. Subjects in whom rATG or infliximab might not be tolerated

         19. Subjects with less than 3000/mm^3 WBC

         20. Subjects with less than 100,000/mm^3 platelets counts

         21. Subjects with systolic blood pressure &lt; 100 mm/Hg

         22. Subjects with symptomatic orthostatic hypotension or currently requiring Midodrine
             for blood pressure support

         23. Subjects from or who have traveled to endemic areas with a history of active
             histoplasmosis or with a CXR consistent with previous active histoplasmosis (no
             serological testing required).

         24. Subjects currently or formerly residing in regions of the US that are highly endemic
             for coccidioidomycosis, and who have a positive serologic test for
             coccidioidomycosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Heeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald E Hricik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suphamai Bunnapradist</last_name>
      <phone>310-794-8516</phone>
      <email>bunnapradist@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Janette Gadzhyan, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Fernandez</last_name>
      <phone>415-353-8380</phone>
      <email>Emilio.Fernandez@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Flavio Vincenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricarda Tomlin</last_name>
      <phone>203-785-2073</phone>
      <email>ricarda.tomlin@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Formica Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ferry</last_name>
      <phone>404-712-1816</phone>
      <email>elizabeth.ferry@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Newell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mawby</last_name>
      <phone>734-936-4811</phone>
      <email>jlmawby@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Milagros Samaniego-Picota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cusanelli Rebecca</last_name>
      <phone>314-362-4109</phone>
      <email>rcusanel@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Wilson</last_name>
      <phone>212-659-8049</phone>
      <email>Douglas.Wilson@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Madhav Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Heeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Sendrey</last_name>
      <phone>216-444-0486</phone>
      <email>sendred2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Emilio Poggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Lee</last_name>
      <phone>216-844-5396</phone>
      <email>tracey.lee@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Donald Hricik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Slivinski</last_name>
      <phone>(204) 787-8662</phone>
      <email>cslivinski@exchange.hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Julie Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.ctotstudies.org/</url>
    <description>Clinical Trials in Organ Transplantation (CTOT)</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 14, 2016</lastchanged_date>
  <firstreceived_date>July 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>infliximab</keyword>
  <keyword>Tissue Donors</keyword>
  <keyword>Remicade</keyword>
  <keyword>Induction Therapy</keyword>
  <keyword>Deceased Donor Kidney Transplant Recipients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
